INTRODUCTION {#S5}
============

The current outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), started in or around December, 2019, in Wuhan\[[@R1]\]. On January 30^th^, 2020 the World Health Organization (WHO) declared COVID-19 a pandemic health emergency\[[@R2]\]. Since then, COVID-19 has continued to spread quickly and has now become the most dangerous pandemic in over 100 years.

An interactive real-time COVID-19 reporting system set up by the Center for Systemic Science and Engineering at Johns Hopkins University\[[@R3]\] shows, as of the time of this writing, more than 3.1 million confirmed cases and over 217,000 deaths worldwide (led by the U.S., with one third of all cases and one quarter of all deaths). Globally, this corresponds to a \~7% case fatality rate, although rates vary widely among countries and subpopulations.

The first pediatric case in the literature was reported on January 2020 in 10-year-old boy from Shenzhen, China, whose family had visited Wuhan\[[@R4]\]. All epidemiological evidence to date suggests that SARS-CoV-2 infection is less severe in children than in adults. In the latest and largest study in the UK, including 16,749 patients hospitalized for COVID-19, only 239 (2%) were \<18 years of age (including 139 who were \<5 years old)\[[@R5]\]. Large studies in Italy and China have also shown very low case-fatality rates in children and adolescents\[[@R6]\]. Understandably, most studies have focused on adult populations, with very few studies and reviews in children. Moreover, accumulating data points to risk factors for severity and mortality in adults (e.g. older age, cardiovascular disease, diabetes, cancer, immunosuppression, obesity, tobacco smoking, etc)\[[@R5], [@R6]\], but there is very scarce evidence on whether or which risk factors exist in children. While COVID-19 is a multi-system disease, it predominantly affects the lungs, and thus it is critically important to understand whether chronic lung diseases place children at higher risk.

The main objective of this study was to identify whether asthma, the most common chronic respiratory disease in children, is a risk factor for SARS-CoV-2 infection or COVID-19 severity in the pediatric population.

METHODS {#S6}
=======

We performed a systematic literature research in three stages: First, we searched PubMed, EMBASE and CINAHL using the terms "SARS-CoV-2 OR COVID-19" AND "systematic review" AND "children 0--18 years of age" to find systemic reviews on the topic, and then reviewed the primary studies included in those reviews. Second, we searched PubMed for "COVID-19 OR SARS-CoV-2" AND "asthma OR wheezing", to directly find any studies on asthma/wheezing and COVID-19, and evaluated whether they included pediatric populations. Third, we repeated search \#2 in [BioRxiv.org](http://BioRxiv.org) and [MedRxiv.org](http://MedRxiv.org) to evaluate whether existing pre-prints may have relevant pediatric asthma information. The last update of the searches was on May 1, 2020.

Both authors (JCR, EF) independently screened and retrieved articles. The same investigators independently assessed full texts of those primary studies included in the systematic review identified. Any discrepancies were resolved by discussion and consensus. If sufficient studies with relevant data were found, the plan was to perform a meta-analysis by asthma status.

RESULTS {#S7}
=======

After removing duplicates, the first search yielded eight systematic reviews\[[@R5], [@R7]--[@R13]\]. Three of them were eliminated because they did include information on clinical characteristics in children\[[@R7]--[@R9]\]. Therefore, we evaluated five systematic reviews done at different periods during the pandemic and thus including somewhat different primary studies\[[@R10]--[@R13]\]. Castagnoli et al.\[[@R10]\] included 18 articles, 17 from China and 1 from Singapore (444 patients \<10 years old and 553 aged 10--19 years), published up to March 3, 2020. Choi et al.\[[@R11]\] included 7 articles from China (225 pediatric patients) up to March 12, 2020. Chang et al.\[[@R12]\] included 9 studies from China (93 pediatric patients) up to March 15, 2020. The review by Ludvigsson\[[@R13]\] included 45 studies from China (the total number of patients was not described) up to March 19, 2020. And Streng et al.\[[@R14]\] included 8 studies from China (ranging from 6 to 2,143 patients) and one survey from Germany (33 patients) in hospitalized children, up to March 31, 2020. After excluding duplicates, we identified and reviewed 67 primary studies included in those five reviews.

None of the primary studies reviewed reported asthma or recurrent wheezing as a comorbidity or risk factor for COVID-19. Instead, some of those studies reported young age (especially children \<1 year of age) as a group with more severe COVID-19. One large Chinese study\[[@R15]\] reported non-respiratory chronic conditions (hydronephrosis, leukemia receiving chemotherapy, and intussusception) among the 3 children required ICU support and mechanical ventilation all had coexisting conditions; one death occurred in the 10-month child with intussusception. Another study reported a patient develop shock with metabolic acidosis requiring ICU\[[@R16]\]; while a report from China\[[@R17]\] described one patient aged 10--19 years who died, without other clinical information, that probably is the same death in a 14-year-old boy described by Dong and colleagues\[[@R18]\]. Unfortunately, the two larger studies in Chinese pediatric patients, Dong et al.\[[@R18]\] (2,413 children) and Wu and MacGoogan\[[@R19]\] (965 children) did not report enough clinical data to identify comorbidities or risk factors for COVID-19 severity. In the German survey of 33 hospitalized children, 4 out of 22 (18%) children with clinical information had "respiratory comorbidities" without further details\[[@R14]\].

Our second search yielded 25 results in PubMed. Of those, four were primary studies that reported on asthma in adults\[[@R20]--[@R23]\]; one other was a guidance statement\[[@R24]\] that referenced a primary report that also included information on asthma in adults\[[@R25]\]. No studies from that search included information on asthma in children, although one case series reported two young children (ages 2 and 3 years) with history of atopic dermatitis and allergic rhinitis, who were hospitalized with COVID-19; both patients recovered\[[@R26]\]. Our third search yielded 26 pre-prints in BioRxiv and 86 in MedRxiv. None of the BioRxiv posts were relevant to our topic. Of the 86 pre-prints in MedRxiv, 14 non-duplicate studies included information on asthma\[[@R27]--[@R40]\], but none of them included specific information in children.

More recently, the CDC published a Morbidity Mortality Weekly Report (MMWR)\[[@R41]\] that included information from 2,572 U.S. children aged \< 18 years. Of those cases, 345 had data on clinical and underlying conditions, and 80 of those children (23%) had at least one underlying condition. The most common underlying conditions were "chronic lung diseases (including asthma)" in 40 children, cardiovascular disease in 25, and immunosuppression in 10; separate information on asthma was not provided. Among the 295 cases for which data on both hospitalization status and underlying medical conditions was available, 28/37 (77%) hospitalized patients had one or more underlying medical condition (including all six patients admitted to an ICU); compared to 30/258 (12%) patients who were not hospitalized\[[@R41]\].

DISCUSSION {#S8}
==========

In a systematic review of the literature, we only found one report described asthma/recurrent wheezing as a potential risk factor for COVID-19 in children. Importantly, none of the largest epidemiological studies including children with COVID-19 reported clinical findings or underlying characteristics to help assess whether asthma -or other chronic lung diseases-constitutes a risk factor for SARS-CoV-2 infection or COVID-19 severity.

COVID-19 affects primarily the lungs, and accordingly several international guidelines have designated some respiratory conditions as a potential risk factor for severe disease. Chinese guidelines\[[@R42]\] state that "children with a history of contact with severe 2019-nCoV infected cases, or with underlying conditions (such as congenital heart disease, bronchial pulmonary hypoplasia, respiratory tract anomaly, with abnormal hemoglobin level, severe malnutrition), or with immune deficiency or immunocompromised status... may become severe cases". A recent statement from the EAACI Section on Pediatrics\[[@R24]\] declared that "patients with asthma (particularly severe or uncontrolled asthma) and immunodeficiency have also been classified to be at increased risk of developing severe COVID-19, based more on common sense rather than mounting evidence". The Global Initiative for Asthma (GINA) recommends avoiding the use of nebulizers due to the increased risk of disseminating COVID-19 to other patients and healthcare staff; they thus recommend the use of pressurized metered dose inhalers (pMDI) as the preferred delivery system during asthma attacks\[[@R43]\]. A recent randomized controlled trial (RCT)\[[@R44]\] showed that even in children with severe asthma exacerbations, administration of albuterol/salbutamol and ipratropium by MDI with valved-holding chamber and mask along with oxygen by nasal cannula was more effective than nebulized administration. GINA\[[@R43]\] and the British Thoracic Society\[[@R45]\] do not recommend stopping oral steroids in the patients already taking them for asthma management, and they do not recommend avoiding them for acute asthma attacks even if due to COVID-19. The U.S. CDC, the Canadian Pediatric Society, and other professional associations have issued guidance for patients with asthma and/or allergies\[[@R46]--[@R48]\]. Other professional organizations, such as the American Academy of Pediatrics and the American Thoracic Society, have published interim guidelines that do not specifically address asthma, likely given a paucity of evidence\[[@R49], [@R50]\].

Rather than a risk factor, a recent review of data in adults found it that both asthma and COPD appear to be under-represented in the comorbidities reported for patients with COVID-19, compared with global estimates of prevalence for these conditions in the general population. This was in contrast to the prevalence of other chronic diseases such as diabetes, which occurred with higher frequency among patients with COVID-19 than the estimated national prevalence\[[@R51]\]; but consistent with several studies that have shown lower-than-expected prevalence of asthma among cases of COVID-19\[[@R20]--[@R23], [@R25]\]. If true, this could be due to several factors, including changes in the immune response or decreased risk secondary to chronic medications such as inhaled corticosteroids (ICS). In-vitro models have shown that ICS may suppress both coronavirus replication and cytokine production\[[@R52], [@R53]\]. And a recent study (in children and adults) showed that patients with asthma and respiratory allergies had reduced angiotensin-converting enzyme 2 (*ACE2*) gene expression in airway cells, suggesting a potential mechanism of reduced COVID-19 risk\[[@R54]\]. This is particularly noteworthy considering that one of the potential explanations for children being generally less affected than adults is the hypothesis that children have lower ACE2 receptor expression in alveolar type 2 cells\[[@R55]\]. However, the lower prevalence of asthma among COVID-19 cases could also stem from bias due to underdiagnosis and under-reporting, or because patients with chronic lung diseases may be especially cautious in practicing physical distancing and other measures to avoid infection. Finally, it is also conceivable that some milder cases of COVID-19 might be confused with exacerbations of respiratory disease, and/or that these patients may be reluctant to seek medical care even when sick and are thus never counted.

CONCLUSIONS {#S9}
===========

After an extensive review of the current literature, only one study reported information on asthma as a potential risk factor for COVID-19 severity -but not mortality- in children. However, the largest studies to date have been limited to a description of the number of cases by age group, and so it remains unclear whether childhood asthma -or other pediatric respiratory diseases- are associated with COVID-19 risk or severity.

We hereby ask the public health community to move beyond confirming what's already known -that the disease affects children and young adults less frequently and severely than older groups- and to study affected pediatric populations in more detail. Does asthma constitute a risk factor for COVID-19 in children? Do asthma severity or control modify the course of the disease? Are asthma medications (particularly ICS and systemic steroids) protective or detrimental? Given the limited numbers of pediatric cases in any one given center/country, collaborative international efforts may be the only way to shed light on the topic. This will be true not just for childhood asthma but for pediatric diseases in general.
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